Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management

Frontiers in Immunology

Liansha Tang¹  Yuwen Zhou¹  Wenbo He²  Qin Zhang³  Weimin Li⁴ 

[1] Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China;Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, China;Department of Postgraduate Student, West China Hospital, Sichuan University, Chengdu, China;Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China;

关键词: immune checkpoint inhibitor;    pneumonitis;    non-small-cell lung cancer;    diagnosis;    management;   

DOI  :  10.3389/fimmu.2021.663986

来源: DOAJ

【 摘 要 】

Immunotherapy that includes programmed cell death-1 (PD-1), programmed cell death- ligand 1 (PD-L1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitors has revolutionized the therapeutic strategy in multiple malignancies. Although it has achieved significant breakthrough in advanced non-small cell lung cancer patients, immune-related adverse events (irAEs) including checkpoint inhibitor pneumonitis (CIP), are widely reported. As the particularly worrisome and potentially lethal form of irAEs, CIP should be attached more importance. Especially in non-small cell lung cancer (NSCLC) patients, the features of CIP may be more complicated on account of the overlapping respiratory signs compromised by primary tumor following immunotherapy. Herein, we included the previous relevant reports and comprehensively summarized the characteristics, diagnosis, and management of CIP. We also discussed the future direction of optimal steroid therapeutic schedule for patients with CIP in NSCLC based on the current evidence.

【 授权许可】

Unknown